EHDN Platform Meeting: Tuesday, 29 September 2026

Tominersen: GENERATION HD2 Results and Key Learnings

Following Roche’s community letter announcing the discontinuation of GENERATION HD2, and EHDN’s Executive Committee statement, we will welcome Peter McColgan, Global Development Leader at Roche, to present the results and key learnings from the Phase 2 clinical trial testing tominersen in Huntington’s disease.

🕓Time: 16:00–17:30 CEST

📍Platform: Zoom